8 Integrated CNS Medication Cases

Balancing CNS medication benefits and risks

Medication decisions for central nervous system conditions require weighing intended benefit against contraindications, interactions, adverse effects, and monitoring needs. The whole regimen matters, including prescription and nonprescription medicines and supplements. Medication changes and urgent treatment decisions require a qualified clinician.

Antidepressants, MAOIs, and serotonin risk

Sertraline should not be started until at least 14 days after stopping an MAOI. At 10 days, the washout period is incomplete, and combining or closely sequencing these medicines can cause serotonin syndrome.

Agitation, sweating, diarrhea, tremor, and unusually brisk reflexes are concerning for serotonin syndrome. The symptoms require urgent clinical assessment; severe or rapidly worsening symptoms require emergency care. Tramadol is also serotonergic and may add risk.

Before starting an antidepressant, review prescription and nonprescription medicines and supplements for serotonergic agents and interactions. Also screen for a history of mania or hypomania, which can affect treatment choice.

Clozapine risks and monitoring

Fever and a sore throat during clozapine treatment can signal infection associated with severe neutropenia. Prompt clinical assessment and an absolute neutrophil count (ANC) are important; a baseline ANC and ongoing ANC monitoring are required during treatment.

Other serious clozapine risks to discuss or monitor include myocarditis or cardiomyopathy, orthostatic hypotension and syncope, seizures, severe constipation or gastrointestinal hypomotility, and metabolic changes. Monitoring and counseling should reflect the person's risks and current prescribing information.

Antipsychotics, including clozapine, carry an increased mortality warning for older adults with dementia-related psychosis and are not approved for that condition.

Lithium interactions and toxicity

Worsening tremor, unsteady walking, and confusion in someone taking lithium raise concern for lithium toxicity. Vomiting and diarrhea can cause fluid and sodium loss, increasing the risk.

Hydrochlorothiazide and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen can raise lithium concentrations. Dehydration may further reduce lithium clearance.

Arrange urgent clinical assessment, including a lithium concentration and renal function; assess fluid and electrolyte status as clinically indicated. Routine care includes monitoring serum lithium and kidney function, assessing thyroid function, reviewing interacting drugs, and reassessing when illness or fluid intake changes occur.

Lamotrigine rash and valproate risks

Valproate can increase lamotrigine exposure, and faster-than-planned dose escalation increases the risk of a serious rash, including Stevens–Johnson syndrome or toxic epidermal necrolysis. A patient who develops a new rash should contact the prescriber promptly for assessment. Lamotrigine labeling advises discontinuation at the first sign of rash unless it is clearly unrelated to the drug. Severe rash, blistering, mucosal involvement, facial swelling, or systemic illness warrants emergency evaluation.

Valproate exposure during pregnancy can cause major congenital malformations, including neural tube defects, and neurodevelopmental harm. Discuss pregnancy intentions and alternatives; use in someone who could become pregnant requires careful, individualized risk–benefit assessment. Obtain liver tests before treatment and monitor as directed by the prescribing information.

Sedatives, opioids, and dependence

Combining opioids with benzodiazepines, zolpidem, alcohol, or other central nervous system depressants can cause profound sedation and respiratory depression, potentially leading to coma or death. Avoid the combination when possible. If a clinician judges it necessary, exposure should be minimized and the patient monitored closely.

Sleep-driving is a complex sleep behavior associated with zolpidem. After such an episode, zolpidem should be discontinued and the prescriber contacted promptly; the patient should not take another dose unless a clinician has reassessed the situation.

Regular benzodiazepine use can cause physical dependence. Abrupt discontinuation may cause serious withdrawal, including seizures, so any reduction should be planned with a clinician and generally tapered.

Parkinson's treatment and medication interactions

Haloperidol blocks dopamine D2 receptors and can worsen rigidity and bradykinesia in Parkinson's disease. Dopamine antagonists can also reduce levodopa's therapeutic effect. Haloperidol decanoate labeling specifically contraindicates that formulation in Parkinson's disease.

Iron salts can reduce carbidopa/levodopa absorption and effectiveness. Review the timing of iron and Parkinson's medication and follow product-specific administration advice.

Before changing treatment, review the indication, dose, timing, and full medication list, including over-the-counter products and supplements, with the prescriber or pharmacist. Do not stop or adjust Parkinson's, psychiatric, or seizure medication without clinical guidance. Treatment choices for agitation or psychosis in Parkinson's disease require particular caution.